Home › Funds › Soleus Capital Management, L.P. › URGN

Soleus Capital Management, L.P. position in URGN

UROGEN PHARMA LTD · Health Care

Soleus Capital Management, L.P. reported holding 829,810 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$30.5M, representing 1.05% of its reported portfolio and ranking #29 among its reported holdings. Soleus Capital Management, L.P. has disclosed URGN holdings in 7 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)829.81K sh
Reported value held$30.54M
Portfolio Weight1.05%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s URGN position evolved

Soleus Capital Management, L.P. first disclosed a stake in URGN in Q3 2023 at 372,000 shares (US$5.2M). The position peaked in Q2 2026 at 829,810 shares, worth US$30.5M. Across 7 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 829,810 shares valued at US$30.5M — an increase of 102,810 shares quarter over quarter.. Notable position changes include a 69% trim in Q3 2025 (shares rose 17% over the following quarter), a 78% trim in Q4 2025 (shares fell 23% over the following quarter), a 385% increase in Q1 2026 (shares rose 105% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 372.00K $5.21M New
Q1 2024 10.00K $150.00K New
Q2 2025 2.19M $29.93M New
Q3 2025 679.00K $13.55M Reduce
Q4 2025 150.00K $3.51M Reduce
Q1 2026 727.00K $13.07M Add
Q2 2026 829.81K $30.54M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has Soleus Capital Management, L.P. held URGN?

Soleus Capital Management, L.P. has disclosed URGN holdings in 7 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in URGN?

As of Q2 2026, Soleus Capital Management, L.P. holds 829.81K shares of URGN (UROGEN PHARMA LTD), valued at $30.54M, representing 1.05% of its reported portfolio and ranking #29.

Has Soleus Capital Management, L.P. been buying or selling URGN?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in URGN. The position peaked in Q2 2026 at 829.81K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.